BREAST CANCER PROGRAM The Breast Cancer Program (BC) was an outgrowth of the basic, translational, population and clinical research of the LCCC Breast Cancer SPORE, which has been continuously funded since 1992. LCCC investment in faculty and infrastructure supports one of the country?s premier clinical and research breast programs, performing important interdisciplinary research in the past decade with members rising to national leadership positions. This knitting together of clinical, basic, and epidemiologic research is the hallmark of the Breast Program, and is reflected in the investment in faculty and resources fostered by including, in the last 5 years, over $10M in genomics/sequencing resources used for institutional as well as large multicenter trials. This commitment is reflected in patient-facing institutional trials examining clinical implications of breast cancer subtypes as well as LCCC leadership of collaborative tissue-based studies through the Translational Breast Cancer Research Consortium (TBCRC) and AURORA-US Project (, a multicenter, multiplatform analysis of DNA, RNA, and other alterations in metastases compared with matched primary tumors. The longitudinal and exceptional investment in the Carolina Breast Cancer Studies (CBCS) represents the largest and most heavily annotated population-based study ever performed addressing racial disparities in breast cancer, behavior and outcome. CBCS has received an additional $5M investment in this cycle and is providing the community with an increased understanding of the full range of breast cancer research from genomics /genetics to health services. Program strategic goals include: 1) genomic and genetic analyses of metastatic and primary breast cancers, 2) bench-to-bedside approaches using murine models, 3) translational discovery and strategies based on human tissue-based correlative science, 4) clinical trials and population- based studies leveraging and applying UNC science and community input to address the root causes of disparities. BC members include clinicians, basic researchers, statisticians, bioinformaticians, epidemiologists, and health services scientists. BC has long-term interest in North Carolina?s minority disparities, following the program?s seminal discoveries of the high incidence of triple negative breast cancer (TNBC) in younger African Americans, the subsequent molecular analysis showing the disparity is even more striking, and the surprising finding that the largest racial disparity in survival is in women with hormone receptor-positive disease, for whom access to care and adherence to treatment are key. The BC Program consists of 21 members who are associated with 10 basic science and 5 clinical departments at UNC-Chapel Hill and affiliated institutions. During the last funding period, program members published 494 cancer-related articles, of which 56% were inter-programmatic and 15% were intra-programmatic (57% collaborative). In 2019, our program members held grants totaling $8.1M (direct cost) in cancer-relevant extramural funding, including $4.0M (direct costs) from the NCI and $1.8M other peer-reviewed funding.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of North Carolina Chapel Hill
Chapel Hill
United States
Zip Code
Nicholls, Thomas J; Nadalutti, Cristina A; Motori, Elisa et al. (2018) Topoisomerase 3? Is Required for Decatenation and Segregation of Human mtDNA. Mol Cell 69:9-23.e6
Becker, Silke; Wang, Haibo; Simmons, Aaron B et al. (2018) Targeted Knockdown of Overexpressed VEGFA or VEGF164 in Müller cells maintains retinal function by triggering different signaling mechanisms. Sci Rep 8:2003
Kim, R D; Alberts, S R; Peña, C et al. (2018) Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer. Br J Cancer 118:462-470
Chiang, Yun-Chen; Park, In-Young; Terzo, Esteban A et al. (2018) SETD2 Haploinsufficiency for Microtubule Methylation Is an Early Driver of Genomic Instability in Renal Cell Carcinoma. Cancer Res 78:3135-3146
Suzuki, Aussie; Long, Sarah K; Salmon, Edward D (2018) An optimized method for 3D fluorescence co-localization applied to human kinetochore protein architecture. Elife 7:
Mohan, Vishwa; Sullivan, Chelsea S; Guo, Jiami et al. (2018) Temporal Regulation of Dendritic Spines Through NrCAM-Semaphorin3F Receptor Signaling in Developing Cortical Pyramidal Neurons. Cereb Cortex :
Haase, Karen P; Fox, Jaime C; Byrnes, Amy E et al. (2018) Stu2 uses a 15-nm parallel coiled coil for kinetochore localization and concomitant regulation of the mitotic spindle. Mol Biol Cell 29:285-294
Casilla-Lennon, Marianne M; Choi, Seul Ki; Deal, Allison M et al. (2018) Financial Toxicity among Patients with Bladder Cancer: Reasons for Delay in Care and Effect on Quality of Life. J Urol 199:1166-1173
Williams, Michelle M; Lee, Linus; Werfel, Thomas et al. (2018) Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers. Cell Death Dis 9:21
Tegowski, Matthew; Baldwin, Albert (2018) Noncanonical NF-?B in Cancer. Biomedicines 6:

Showing the most recent 10 out of 1525 publications